Dr Reddy’s Halts Commercial Semaglutide Shipments After API Problem; Shares Slip
Dr Reddy’s Laboratories has paused commercial deliveries of its semaglutide product after certain batches were found out of specification owing to an active pharmaceutical ingredient (API) issue. The company is investigating the root cause and undertaking corrective measures. Shares fell sharply on the news, and a conference call has been scheduled…